Moderna Stock Soars on Promising Coronavirus Vaccine Trial News

Shares of Moderna's (NASDAQ: MRNA) leapt 7% on Wednesday, furthering the biotech's torrid gains -- of more than 315% -- so far in 2020. 

On Tuesday, a peer-reviewed interim analysis of Moderna's phase 1 study of its COVID-19 vaccine, mRNA-1273, was published in The New England Journal of Medicine. The results showed that neutralizing antibodies -- which researchers are hopeful will help to prevent infection by the novel coronavirus that causes COVID-19 -- were found in 100% of evaluated participants in the study. 

Investors cheered encouraging news regarding Moderna's experimental COVID-19 vaccine. Image source: Getty Images.

Continue reading

Source Fool.com